Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adrenomedullin for CADASIL (AMCAD)
NCT06072118Phase 2Completed
- Sponsor
- National Cerebral and Cardiovascular Center
- Start
- Jan 2022
- Primary completion
- Jan 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fispemifene in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), sponsored by National Cerebral and Cardiovascular Center. Primary endpoint: Cerebral blood flow change rate evaluated by arterial spin labeling at 28 days. Started Jan 2022; status: completed.
02
Drugs
fispemifene
03
Conditions
cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
Beyond the preview
Go deeper on NCT06072118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06072118.